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Abstract
Context: There is a lack of comprehensive data regarding the factors that influence
the diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI)
to detect and localize clinically significant prostate cancer (csPCa).
Objective: To systematically review the current literature assessing the factors
influencing the variability of mpMRI performance in csPCa diagnosis.
Evidence acquisition: A computerized bibliographic search of Medline/PubMed
database was performed for all studies assessing magnetic field strength, use of an
endorectal coil, assessment system used by radiologists and inter-reader variabili-
ty, experience of radiologists and urologists, use of a contrast agent, and use of
computer-aided diagnosis (CAD) tools in relation to mpMRI diagnostic accuracy.
Evidence synthesis: A total of 77 articles were included. Both radiologists’ reading
experience and urologists’/radiologists’ biopsy experience were the main factors
that influenced diagnostic accuracy. Therefore, it is mandatory to indicate the
experience of the interpreting radiologists and biopsy-performing urologists to
support the reliability of the findings. The most recent Prostate Imaging ReportingPI-
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assessment system for csPCa, given the simplified and standardized approach as
well as its particular added value for less experienced radiologists. Biparametric
MRI had similar accuracy to mpMRI; however, biparametric MRI performed better
with experienced readers. The limited data available suggest that the combination
of CAD and radiologist readings may influence diagnostic accuracy positively.
Conclusions: Multiple factors affect the accuracy of mpMRI and MRI-targeted
biopsy to detect and localize csPCa. The high heterogeneity across the studies
underlines the need to define the experience of radiologists and urologists,
implement quality control, and adhere to the most recent PI-RADS assessment
guidelines. Further research is needed to clarify which factors impact the accuracy
of the MRI pathway and how.
Patient summary: We systematically reported the factors influencing the accuracy
of multiparametric magnetic resonance imaging (mpMRI) in detecting clinically
significant prostate cancer (csPCa). These factors are significantly related to each
other, with the experience of the radiologists being the dominating factor. In order
to deliver the benefits of mpMRI to diagnose csPCa, it is necessary to develop
expertise for both radiologists and urologists, implement quality control, and
adhere to the most recent Prostate Imaging Reporting and Data System assessment
guidelines.
© 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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Over the last 10 yr, the diagnostic pathway of prostate
cancer (PCa) has changed significantly by the advent of
multiparametric magnetic resonance imaging (mpMRI)
[1,2]. As shown by recently published randomized con-
trolled trials, head-to-head comparisons, and a Cochrane
meta-analysis [3–8], mpMRI is the best technique to detect
and localize suspicious areas for clinically significant
prostate cancer (csPCa), and it allows performing MRI-
targeted biopsy (MRI-TBx) [9]. The value of mpMRI and
MRI-TBx over systematic transrectal ultrasound (TRUS)
biopsy is in reducing diagnoses of insignificant PCa and
potentially avoiding unnecessary prostate biopsies in men
with negative mpMRI scans. Detection and localization of
csPCa are slightly but not significantly better with mpMRI
than with TRUS biopsy.
Acquisition and interpretation of prostate mpMRI are
evolving with ongoing improvements, which influence its
accuracy. These include magnetic field strength, gradient
strength, use of an endorectal coil (ERC) [10], different
versions of assessment systems, reader experience and
inter-reader variability, potential to avoid a contrast agent
(ie, biparametric MRI [bpMRI]), and use of computer-aided
diagnosis (CAD) and deep-learning tools. Another factor
that influences the accuracy of the MRI pathway is the
experience of operators performing MRI-TBx. These show a
significant variation across reported series [4], affecting the
risk of bias of the available data and preventing robust
systematic analyses. Moreover, aiming at assessing the
variation of mpMRI diagnostic accuracy, variability of
biopsy protocols and histopathological reference standards,
and heterogeneity of PCa prevalence among different
cohorts with the consequent variation of the negative
predictive value (NPV) of mpMRI make comparison of
studies even more challenging [11].Please cite this article in press as: Stabile A, et al. Factors Influencin
Resonance Imaging in Detecting Clinically Significant Prostate Ca
https://doi.org/10.1016/j.euo.2020.02.005Despite the large number of studies reporting the
accuracy of mpMRI, there is a lack of comprehensive data
that specifically address the difference of mpMRI execution
and performance. Given the promising role of MRI in csPCa
diagnosis, there is a need to systematically review the
current literature regarding the factors that influence the
variability of mpMRI in the diagnosis of csPCa.
2. Evidence acquisition
2.1. Objective
We aimed to systematically review the current literature
assessing the factors influencing the variability of mpMRI
performance in detecting csPCa. Magnetic field strength
(1.5 vs 3.0 T, including importance of the gradient strength),
use of an ERC, assessment system used by the radiologist,
inter-reader variability, experience of the radiologists and
urologists, use of bpMRI, and use of CAD or deep learning or
machine learning for mpMRI assessment were considered
potential influencing factors.
2.2. Search strategy
Data collection was conducted in accordance with the
Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) statement [12]. A computerized
bibliographic search of Medline/PubMed database was
searched from inception to June 23, 2019. The search terms
used were (prostate cancer OR prostate adenocarcinoma)
AND (MRI OR magnetic resonance) AND (coil OR endorectal
coil OR surface coil OR magnetic field OR reporting system
OR PI-RADS OR Likert OR inter-reader variability OR inter-
reader agreement OR biparametric OR radiologist experi-
ence OR urologist experience OR learning curve OR CAD ORg Variability in the Performance of Multiparametric Magnetic
ncer: A Systematic Literature Review. Eur Urol Oncol (2020),
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gence OR neural network).
2.3. Inclusion criteria
As recommended by the PRISMA guidelines, we used the
population, intervention, comparator, and outcome (PICO)
approach to define study eligibility [12]. Reports were
considered relevant if they provided comparative data on
the relationship between the aforementioned factors. The
performance of mpMRI was defined as PCa detection at
either prostate biopsy or after radical prostatectomy. Thus,
studies assessing one of the factors without providing any
comparison (eg, providing data regarding the accuracy of
1.5 T mpMRI or bpMRI alone) were not included in this
review. Noncomparative studies, case reports, editorials,
letters, review articles, and meeting abstracts were also not
included.
2.4. Systematic review process
Two authors (A.S. and F.G.) independently reviewed a total
of 2013 abstracts and selected 77 studies that were finally
included in the systematic review for full-text evaluation.
Fig. 1 shows the PRISMA flowchart describing the selection
process.
2.5. Data extraction
Data were independently extracted from all included
studies by the same two authors. A standardized dataFig. 1 – Preferred Reporting Items for Systematic Reviews and Meta-analysis flo
resulting in the inclusion of full studies in the review. MRI = magnetic resonan
Please cite this article in press as: Stabile A, et al. Factors Influencin
Resonance Imaging in Detecting Clinically Significant Prostate Ca
https://doi.org/10.1016/j.euo.2020.02.005extraction form was created a priori and used to collect data
on the study design, number of participants, mpMRI
protocol, radiologist experience, and outcome.
2.6. Data analysis
A comprehensive and narrative synthesis of included
studies was performed, since a quantitative meta-analytic
synthesis was not possible due to the heterogeneity of the
studies.
2.7. Risk of bias assessment
The risk of bias and applicability concern in individual studies
was assessed independently by the same two authors using
the Quality Assessment of Diagnostic Accuracy Studies-2
(QUADAS-2) criteria [13]. The presence of baseline con-
founding factors or selection bias, as well as the presence of
any bias within mpMRI protocols, mpMRI interpretation,
biopsy protocol, and histopathological reference standard,
was assessed (Fig. 2 and Supplementary Fig. 1).
3. Evidence synthesis
Overall, 2013 publications were found. If it was not clear
from the abstract whether the paper might contain relevant
data, the full paper was assessed. Seventy-seven articles
were included in the final analysis (Fig. 1). Single studies are
described in detail in Tables 1–4 and Supplementary
Tables 1–3.w diagram showing the outcome of the initial and additional searches
ce imaging.
g Variability in the Performance of Multiparametric Magnetic
ncer: A Systematic Literature Review. Eur Urol Oncol (2020),
Table 1 – List of studies comparing different mpMRI assessment systems.
Author [ref] Year Study design Number of
patients
Scoring
systems
used
MRI protocol Number of
radiologists
Definition of csPCa Reference
standard
Key findings
Auer et al [34] 2017 Prospective (v1)
and retrospective
(v2.0)
50 PI-RADS v1
and v2
T2-WI, DWI,
and DCE
2 Low grade (Gleason score
3+4) vs high-grade
(Gleason score 4+3)
Radical
prostatectomy
* PI-RADS v1 detects tumor better than v2
(AUC: 0.96 vs 0.90)
* PZ lesions: PI-RADS v1 (AUC: 0.97) vs v2
(AUC: 0.92)
* TZ lesions, PI-RADS v1 (AUC: 0.96) vs v2
(AUC: 0.90)
* PI-RADS v2 resulted in significantly more
false-negative results (3% vs 14%) and a
similar true positive result (82% vs 80%)
De Visschere
et al [35]
2016 Retrospective 245 PI-RADS v1
and v2
T2-WI, DWI,
DCE, and MRSI
1 Gleason score 7
(including 3 +4 with
prominent but not
predominant Gleason
4 component), and/or
tumor volume of 0.5 cc,
and/or tumor stageT3a
MRI-TBx * PI-RADS v1 and v2 overall assessment
scores were significantly higher (p < 0.001)
in patients with csPCa
* ROC curve: 0.82 for PI-RADS v1 and
0.79 for PI-RADS v2.0 (p > 0.05)
* Using a threshold of 3, sensitivity was
88.2% and 79.2% (p= 0.001) and specificity
was 64.4% and 67.3% (p > 0.05) with PI-RADS
v1 and v2, respectively
Feng et al [37] 2016 Retrospective 401 PI-RADS v1
and v2
T2-WI, DWI,
and DCE
1 – MRI-TBx * AUC: 0.889 for PI‑RADS v1 and 0.942 for
PI‑RADS v2 (p =0.0001) pooling TZ and PZ
together
* Higher sensitivity in the TZ (96% vs 76%,
p = 0.003), similar specificity (90% vs 84%,
p = 0.227), and higher accuracy (93% vs 81%,
p = 0.002) for PI‑RADS v2
Hoffmann
et al [38]
2018 Prospective 58 PI-RADS v1
and v2
T2-WI, DWI,
and DCE
2 Epstein criteria (PSA
density 0.15ng/ml/g,
Gleason score >3 +3,
presence of PCa in >3
cores with >50%
involvement in any of the
cores
Biopsy (n =58)
and radical
prostatectomy
(n =29)
* Substantial agreement between
radiologists (PI‑RADS v.1: kappa 0.71;
PI‑RADS v.2: kappa 0.69)
Krishna
et al [40]
2017 Retrospective 47 PI-RADS v1
and v2
T2-WI, DWI,
and DCE
3 Gleason score 3 +4 with
tumor foci 0.5 cm3
Radical
prostatectomy
* Higher sensitivity for PI-RADS v1 (p = 0.01
and 0.03, radiologists 1 and 2)
* Moderate interobserver agreement for PI-
RADS v2 (k = 0.41) and slight to substantial
agreement for PI-RADS v1 (T2-WI, k = 0.32;
DWI, k = 0.52; DCE MRI, k = 0.13)
Polanec
et al [39]
2016 Retrospective 65 PI-RADS v1
and v2
T2-WI, DWI,
and DCE
2 – MRI-TBx * Almost perfect inter-reader agreement for
PI-RADS v2 and v1 (k = 0.71 and k =0.81,
respectively).
* No difference in sensitivity between
radiologists (p >0.05)
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Table 1 (Continued )
Author [ref] Year Study design Number of
patients
Scoring
systems
used
MRI protocol Number of
radiologists
Definition of csPCa Reference
standard
Key findings
* Higher specificity using PI-RADS v1
compared with PI-RADS v2 (radiologist 1:
p = 0.0078, radiologist 2: p = 0.0313)
Renard-Penna
et al [41]
2015 Prospective 118 (but only 50 for
inter-reader
agreement)
PI-RADS v1
and Likert
T2-WI, DWI,
and DCE
2 Cancer core length 3mm
and/or Gleason score 4
MRI-TBx * Good levels of agreement for the Likert
scale (k = 0.80) and summed PI-RADS
(k = 0.73) scoring systems
* Good levels of agreement for PI-RADS T2-
WI (k = 0.61) and DCE (k = 0.71), while only
fair consistency (k = 0.53) for DWI
Rosenkrantz
et al [42,66]
2013 Retrospective 70 PI-RADS v1
and Likert
T2-WI, DWI,
and DCE
3 Any tumor >3mm in
maximal diameter
Radical
prostatectomy
* For tumors with Gleason score 7:
- Sensitivity was higher with PI-RADS than
with Likert for radiologist 1 (88.6% vs 82.6%,
p = 0.032)
- Sensitivity was similar for radiologist 2
(78% vs 76%, p = 0.467) and radiologist 3 (77%
vs 81%, p = 0.125).
* In the TZ, accuracy was lower with PI-
RADS than with Likert for radiologist 1 (70%
vs 87%, p < 0.001), radiologist 2 (88% vs 93%,
p = 0.002), and radiologist 3 (83% vs 91%, p <
0.001)
Schaudinn
et al [43]
2019 Retrospective 40 PI-RADS v1
and v2
T2-WI, DWI,
and DCE
2 – Radical
prostatectomy
* PI-RADS v2 showed a trend toward lower
sensitivities for:
- Radiologist 1: 72% (v1) vs 64% (v2;
p = 0.426)
- Radiologist 2: 78% (v1) vs 69% (v2;
p = 0.402)
* Trends were more pronounced in the TZ
(p = 0.313) and for low-grade PCa (p =0.691)
Tewes
et al [44]
2016 Retrospective 54 PI-RADS v1
and v2
T2-WI, DWI,
and DCE
2 – MRI-TBx * Agreement between PI-RADS scores was
good (reader 1: k = 0.62; reader 2: k = 0.64)
* Interobserver agreement was moderate
with PI-RADS v2 (k = 0.56) and fair with v1
(k = 0.39)
Wang
et al [36]
2018 Prospective 77 PI-RADS v1
and v2.0
T2-WI, DWI,
and DCE
2 Gleason score 7 MRI-TBx * PI‑RADS v2 exhibited a higher AUC (0.888)
than PI‑RADS v1 (0.869)
* PI‑RADS v2 had higher sensitivity (75% vs
69%) but lower specificity (90% vs 96%) when
than PI‑RADS v1 for the assessment of PCa in
the TZ
AUC= area under the curve; csPCa = clinically significant prostate cancer; DCE=dynamic contrast-enhanced imaging; DWI =diffusion-weighted imaging; mpMRI =multiparametric MRI; MRI =magnetic resonance imaging;
MRI-TBx =MRI targeted biopsy; MRSI =magnetic resonance spectroscopic imaging; PCa =prostate cancer; PI-RADS=Prostate Imaging Reporting and Data System; PZ =peripheral zone; ROC= receiver operating
characteristics; T2-WI = T2-weighted imaging; TZ = transition zone.
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Table 2 – List of studies assessing the relationship between mpMRI performance and radiologist and urologist experience.
Author Year Study design Trainee Training No. of patients Learning curve definition Definition of
csPCa
Key findings
Akin et al [47] 2010 Prospective 11 radiology fellows * Baseline: 15 MRI scans
* 5 interactive lectures
* 200 MRI scans over
10 wk
– Accuracy in identifying
peripheral and transitional
tumors and ECE
– * Peripheral PCa: AUC
increased from 0.52 to
0.66 (p < 0.001) after the
interactive course and
then remained stable
* Transitional PCa: AUC
increased from 0.49 to
0.64 (p= 0.01) after the
interactive courses and
up to 0.68 (p = 0.001) at
the end of training
* ECE: AUC increased
from 0.50 to 0.81 (p <
0.0001)
Garcia-Reyes et al [48] 2015 Retrospective 5 radiology fellows 31 MRI scans reinterpreted
after 5 yr of dedicated
education program
– Accuracy and confidence in
identifying overall and
anterior PCa
Gleason score
3+4
* Index PCa detection:
from 74.2% to 87.7%
(p =0.003)
* Confidence: from
3.75 to 4.22 (scale 1–5)
* Anterior PCa
detection: from 54.3% to
94.3% (p= 0.001)
Rosenkrantz et al [49] 2017 Prospective 6 2nd-year radiology
residents
124 MRI scans using PI-
RADS v1 score. Readers
divided between with and
without feedback
– Progressive accuracy,
sensitivity, specificity, PPV,
and NPV
Gleason score
3+4
* Initial rapid
improvement in AUC that
slowed after
40 examinations
* AUC and sensitivity
improved from 58% and
56% up to 77% and 82%,
respectively, in the group
with feedback.
* Feedback did not
affect the accuracy
improvement
significantly
* Feedback resulted to
be more useful for
transitional zone PCa
Pickersgill et al [50] 2019 Retrospective 9 radiologists with
2–11 yr of experience
– 459 men receiving
MRI for suspicion
of PCa
Sensitivity, specificity, PPV,
and NPV
Gleason score
3+4
* Radiologist experience
(>500 scans) was
associated with
decreased sensitivity and
NPV
Rosenkrantz et al [51] 2019 Prospective 3 2nd-year radiology
residents
Two separate sets of
60 MRI scans reported
before and after an online
course using PI-RADS v2
– Accuracy, sensitivity,
specificity, PPV, and NPV
Gleason score
3+4
* Online course
significantly improved
sensitivity (from 57.8% to
73.3%, p = 0.003) and NPV
(from 69.2% to 78.2%,
p = 0.049)
E
 U
 R
 O
 P
 E
 A
 N
 U
 R
 O
 L
 O
 G
 Y
 O
 N
 C
 O
 L
 O
 G
 Y
 X
 X
 X
 (
 2
 0
 1
 9
 )
 X
 X
 X
 –
 X
 X
 X
6 EU
O
-306;
 N
o.
 of
 Pages
 23
Please
 cite
 th
is
 article
 in
 p
ress
 as:
 Stabile
 A
,
 et
 al.
 Factors
 In
fl
u
en
cin
g
 V
ariability
 in
 th
e
 Perform
an
ce
 of
 M
u
ltip
aram
etric
 M
agn
etic
R
eson
an
ce
 Im
agin
g
 in
 D
etectin
g
 C
lin
ically
 Sign
ifi
can
t
 Prostate
 C
an
cer:
 A
 System
atic
 Literatu
re
 R
eview
.
 Eu
r
 U
rol
 O
n
col
 (2020),
h
ttp
s://d
oi.org/10.1016/j.eu
o.2020.02.0
05
Table 2 (Continued )
Author Year Study design Trainee Training No. of patients Learning curve definition Definition of
csPCa
Key findings
* No increase for
specificity and PPV
* Accuracy of single PI-
RADS score assignment
did not improve
Gaziev et al [55] 2016 Retrospective 3 urologists
experienced in
standard biopsy, naïve
for MRI-TBx
– 340 men
undergoing MRI-
TBx
MRI-TBx PCa detection
across the entire cohort
divided into five
subcohorts timely
consecutive
Gleason score
3+4
* Increase in MRI-TBx
PCa detection (from 27%
to 63%) between the first
and last 70 men
* Improvement in MRI
NPV (up to 89% in the
most recent cohort)
Calio et al [56] 2017 Retrospective – – 1528 biopsy-naïve
men undergoing
MRI-TBx
MRI-TBx csPCa detection
across the entire cohort
divided into 3 subcohorts
timely consecutive over
9 yr
Gleason score
3+4
* 13% increase in csPCa
detection rate by MRI-
TBx over the study period
* csPCa detection rate at
MRI-TBX increased even
after multivariate
adjustment
Meng et al [57] 2018 Retrospective 4 urologists
experienced in
standard biopsy
– 1595 men with
previous negative
biopsy undergoing
MRI-TBx
MRI-TBx csPCa detection
over the study period and
at repeat MRI-TBx
Gleason score
3+4
* csPCa detection
increased 26% with time
in men with a PI-RADS 4/
5 region of interest
* On repeat MRI-TBx,
53% of those with PI-
RADS 4–5 demonstrated
csPCa discordance
compared with previous
biopsy
Mager et al [58] 2017 Retrospective 1 1st-year resident
naïve for MRI-TBx
– 84 consecutive
MRI-TBx
MRI-TBx quotient and
biopsy time
– * Significant
improvement in both
detection quotient and
biopsy time after
42 procedures, flattening
after 63 biopsies
Kasabwala et al [59] 2018 Retrospective – – 173 consecutive
MRI-TBx
MRI-TBx accuracy defined
as distance between
planned and actual core
trajectories stored on MRI-
TBx fusion software
– * Significant
improvement in targeted
biopsy accuracy occurred
in up to 98 cases (p <
0.01)
Halstuch et al [60] 2019 Retrospective Urologists naïve for
MRI-TBx
– 779 men
undergoing either
transrectal (523) or
transperineal (256)
MRI-TBx
Urologist experience was
coded at the total number
of MRI-TBx before each
procedure
Gleason score
3+4
* 104 transrectal MRI-
TBx and
119 transperineal MRI-
TBx are at least necessary
to reach the best PCa
detection
E
 U
 R
 O
 P
 E
 A
 N
 U
 R
 O
 L
 O
 G
 Y
 O
 N
 C
 O
 L
 O
 G
 Y
 X
 X
 X
 (
 2
 0
 1
 9
 )
 X
 X
 X
 –
 X
 X
 X
 
7
EU
O
-306;
 N
o.
 of
 Pages
 23
Please
 cite
 th
is
 article
 in
 p
ress
 as:
 Stabile
 A
,
 et
 al.
 Factors
 In
fl
u
en
cin
g
 V
ariability
 in
 th
e
 Perform
an
ce
 of
 M
u
ltip
aram
etric
 M
agn
etic
R
eson
an
ce
 Im
agin
g
 in
 D
etectin
g
 C
lin
ically
 Sign
ifi
can
t
 Prostate
 C
an
cer:
 A
 System
atic
 Literatu
re
 R
eview
.
 Eu
r
 U
rol
 O
n
col
 (2020),
h
ttp
s://d
oi.org/10.1016/j.eu
o.2020.02.0
05
Table 2 (Continued )
Author Year Study design Trainee Training No. of patients Learning curve definition Definition of
csPCa
Key findings
* 109 transrectal MRI-
TBx and
124 transperineal MRI-
TBx are at least necessary
to reach the minimum
biopsy time
Stabile et al [61] 2018 Retrospective 3 urologists
experienced in
standard biopsy, naïve
for MRI-TBx
– 244 men
undergoing MRI-
TBx
Urologist experience was
coded at the total number
of MRI-TBx before each
procedure
Gleason score
3+4
* Urologist experience
was associated with
better csPCa detection
after multivariate
adjustment
* Significant increase in
csPCa detection during
the first 60 procedures
and a flattening after
80 procedures
* Transperineal MRI-TBx
was less affected by
urologist experience
achieving good csPCa
detection since the first
procedures
Westhoff et al [62] 2019 Retrospective 22 urologists (9 senior;
13 resident)
– 210 consecutive
MRI-TBx
Urologist experience was
coded at the total number
of MRI-TBx before each
procedure
Gleason score
3+4
* 8 MRI-TBx as the
necessary threshold for
experience
* PCa detection rates for
low and high
experienced (according
to the threshold) were
23% and 49%, respectively
(p < 0.001)
AUC= area under the curve; csPCa = clinically significant prostate cancer; ECE= extracapsular extension; MRI =magnetic resonance imaging; MRI-TBx=MRI-targeted biopsy; NPV=negative predictive value; PCa =prostate
cancer; PI-RADS=Prostate Imaging Reporting and Data System; PPV=positive predictive value.
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Table 3 – List of studies assessing the inter-reader variability of mpMRI.
Author Year Study design Reporting
system
No. of MRI/lesions
reported
No. of readers Reader’s
experience
Definition of
csPCa
Key findings
Quentin et al [63] 2012 Retrospective,
single institute
Likert 108 predefined lesions 3 blinded 3 yr – * Agreement of T2-weighted images, DWI,
and DCE k was 0.49, 0.97, and 0.77,
respectively
* PPV range 71–88% (k =0.48)
* AUC range 88–96% (k = 0.90)
Schimmöller et al [65] 2013 Retrospective,
single institute
PI-RADS v1 164 premarked lesions in
67 MRI
3 blinded 4, 3, and 2 yr – * Agreement for all lesions was good to
moderate (T2-WI, k = 0.55; DWI, k =0.64; DCE
MRI, k = 0.65)
* For malignant lesions agreement was
better than for benign lesions
Rosenkrantz et al [42,66] 2013 Retrospective,
single institute
Likert and PI-
RADS v1
55 MRI 3 blinded 2 experienced
readers and one
inexperienced
Gleason score
3+4
* Overall agreement between experienced
readers was strong and for both the PI-RADS
and the Likert scale
* Overall agreement between experienced
and inexperienced readers was moderate to
poor
* Agreement in the PZ was better for Likert
than for PI-RADS
Rosenkrantz et al [71] 2016 Retrospective,
multi-institute
PI-RADS v2 Two sessions of 40 and
80 MRI with intersession
training in between
6 blinded 6 experienced Gleason score
3+4
* No substantial difference was observed in
the inter-reader agreement between sessions
* Agreement for PI-RADS 4 was 0.593 in
PZ and 0.509 in TZ
* Agreement of PZ and TZ for PI-RADS 3
was 81.9% and 76.4%, respectively
* Overall agreement for PI-RADS 3 and 4
was 79.2% and 77.8%, respectively
Mussi et al [67] 2019 Retrospective,
single institute
PI-RADS v2 160 premarked lesions for
160 MRI single slides
8 blinded Between 100 and
>2000 MRI
reported
Gleason score
3+4
* Coefficient of concordance according to
categories was 0.71 considering both zones,
0.72 for PZ and 0.44 for TZ
* Agreement for PI-RADS 3 was 0.48 in PZ
and 0.57 in TZ
Glazer et al [68] 2017 Retrospective,
single institute
PI-RADS v2 59 patients with a single
lesion each
3 blinded 1, 4, and 11yr Gleason score
3+4
* Overall suspicion score agreement was
moderate (k = 0.45)
* There was moderate agreement among
overall PI-RADS scores in the PZ (k = 0.46)
and fair agreement in the TZ (k = 0.36)
Girometti et al [69] 2019 Retrospective PI-RADS v2 48 preoperative MRI 3 unblinded;
readers aware of
the presence of PCa
2, 6, and 8 yr Gleason score
3+4
* Moderate agreement in assigning PI-RADS
categories to all PCa (k = 0.53) and csPCa
(k = 0.47)
* Assessing csPCa with PI-RADS 4 had
higher agreement than PI-RADS 3 (k = 0.63
vs k = 0.57)
* Agreement was higher between more
experienced readers
Müller et al [70] 2018 Retrospective, two
institutions
PI-RADS v1 and
v2
126 men with positive MRI
received second MRI
NR NR Gleason score
3+4
* Poor level of agreement between the two
MRI scans and a statistically significant
difference in PI-RADS scores
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Table 3 (Continued )
Author Year Study design Reporting
system
No. of MRI/lesions
reported
No. of readers Reader’s
experience
Definition of
csPCa
Key findings
Smith et al [72] 2019 Retrospective,
multi-institute
PI-RADS v2 102 MRI read twice with
wash-out period in
between
4 blinded Moderate and high
experience
Gleason
score3+4
* Overall intrareader reproducibility was
moderate to substantial (k = 0.43–0.67)
* Overall inter-reader reproducibility was
poor to moderate (k = 0.24)
* Readers with more experience showed
greater inter-reader reproducibility
Hansen et al [73] 2017 Retrospective,
multi-institute
Likert 158 MRI 28 blinded NR for referring
readers; second
readers >1000 MRI
reported
Gleason score
3 +4
* Overall disagreement was 54% (86/158
MRI scans)
*MRI scans were more often called negative
by expert readers (41% vs 20%)
* Second readings of MRI by expert readers
significantly improved NPV and PPV
Sonn et al [78] 2019 Retrospective,
single institute
PI-RADS v1 and
v2
409 MRI 9 blinded Median 6 yr (range
1–25)
Gleason score
3 +4
* csPCa detection rate was 3–27% for PI-
RADS 3 lesions, 23–65% for PI-RADS 4, and
40–80% for PI-RADS 5 across radiologists
* 13–60% of men with a PI-RADS <3 lesion
harbored csPCa
* AUC varied from 0.69 to 0.81 across
readers
Greer et al [74] 2019 Retrospective,
multi-institute
PI-RADS v2 163 MRI 9 blinded 3 high level
(<2000 last 2 yr)
Gleason score
3 +4
* Sensitivity for index lesions was 80.9%,
comparable across reader experience
3 moderate (500–
2000 last 2 yr)
* Highly experienced readers had 84.0%
specificity versus 55.2% for all others (p <
0.001)
3 low (<500 last
2 yr)
* Inter-reader agreement was excellent for
detecting index lesions (k = 0.87)
* Agreement on PI-RADS v2 category
assignment of index lesions was moderate
(k =0.419)
Ke et al [75] 2018 Retrospective,
single institute
PI-RADS v2 183 MRI 6 blinded 6 mo and 2, 3, 4, 5,
or 17 yr
– * Inter-reader agreement was weak to
moderate (k = 0.506)
* AUC varied between 0.88 and 0.95
Purysko et al [76] 2017 Retrospective,
single institute
PI-RADS v2 170 MRI with
premarked lesions
2 blinded 7 yr Gleason score
3 +4
* AUC for readers 1 and 2 were 0.871 and
0.882, respectively
* AUCs were greater for PZ
* Agreement was good overall (k = 0.63) and
fair for TZ lesions (k = 0.53) for PI-RADS 3
* Agreement was excellent for PI-RADS 4
Pickersgill et al [77] 2018 Retrospective,
single institute
PI-RADS v2 32 MRI 4 blinded 0–548 MRI
reported
Gleason score
3 +4
* For PI-RADS 3, AUC for csPCa ranged
between 47% and 75% (p < 0.001)
* Team readings did not improve AUC
AUC=area under the curve; csPCa= clinically significant prostate cancer; DCE=dynamic contrast-enhanced imaging; DWI=diffusion-weighted imaging; MRI =magnetic resonance imaging; NPV=negative predictive value;
NR=not reported; PCa =prostate cancer; PI-RADS=Prostate Imaging Reporting and Data System; PPV=positive predictive value; PZ =peripheral zone; T2-WI = T2-weighted imaging; TZ = transition zone.
E
 U
 R
 O
 P
 E
 A
 N
 U
 R
 O
 L
 O
 G
 Y
 O
 N
 C
 O
 L
 O
 G
 Y
 X
 X
 X
 (
 2
 0
 1
 9
 )
 X
 X
 X
 –
 X
 X
 X
10 EU
O
-306;
 N
o.
 of
 Pages
 23
Please
 cite
 th
is
 article
 in
 p
ress
 as:
 Stabile
 A
,
 et
 al.
 Factors
 In
fl
u
en
cin
g
 V
ariability
 in
 th
e
 Perform
an
ce
 of
 M
u
ltip
aram
etric
 M
agn
etic
R
eson
an
ce
 Im
agin
g
 in
 D
etectin
g
 C
lin
ically
 Sign
ifi
can
t
 Prostate
 C
an
cer:
 A
 System
atic
 Literatu
re
 R
eview
.
 Eu
r
 U
rol
 O
n
col
 (2020),
h
ttp
s://d
oi.org/10.1016/j.eu
o.2020.02.0
05
Table 4 – List of studies assessing the comparison between bpMRI and mpMRI.
Author Year Study design No. of
patients
MRI reporting No. of readers
(experience)
Reference
standard
Outcome Key findings
Stanzione et al [82] 2016 Retrospective 82 bpMRI then mpMRI
with 20–30 d
interval
2 blinded (10 and
14yr)
Mixed Any PCa * bpMRI and mpMRI showed similar
performance for PCa detection with AUC
0.91 and 0.93, respectively (p > 0.05)
Thestrup et al [83] 2016 Retrospective 204 mpMRI then bpMRI
with 2 mo interval
2 blinded
(experienced)
Mixed csPCa defined as Gleason
score 3+4
* mpMRI: sensitivity 0.93–1.0, specificity
0.04–0.16, PPV 0.34–0.36, NPV 0.81–1.00
* bpMRI: sensitivity 0.94–0.96, specificity
0.15, PPV 0.36, NPV 0.83–0.87
Lee et al [84] 2017 Retrospective 123 55 and 68 men
received mpMRI
and bpMRI,
respectively
2 blinded
(experienced)
Mixed csPCa defined as Gleason
score 3+4
* No differences in PCa and csPCa detection
rate (41.8% vs 30.9%, p =0.208 and 82.6% vs
76.2%, p =0.598)
* Similar detection of PCa among men who
had suspicious lesions in the bpMRI and
bpMRI groups (63.3% and 62.5%, respectively,
p =0.7)
Kuhl et al [85] 2017 Retrospective 542 bpMRI then mpMRI
in the same session
4 blinded (2–9yr) Mixed csPCa defined as Gleason
score 3+4
* bpMRI and mpMRI csPCa detection was
25.6% (mpMRI detected 1 additional case of
csPCa)
* AUC was 89.1% and 87.2% for bpMRI and
mpMRI, respectively
* PPV was 73.8% vs 69.8% for bpMRI vs
mpMRI
Nieuwenhove et al [86] 2019 Retrospective 90 1.5 T bpMRI then
3T mpMRI after
1 mo
2 blinded (2 and
10yr)
TRUS-Bx plus
MRI-TBx
csPCa defined as Gleason
score 3+4
* Compared with mpMRI, on the lesion-
based analysis, bpMRI AUC 0.961 (p < 0.001),
sensitivity 95%, specificity 97%, PPV 99%, NPV
89%
* On the patient-based analysis, bpMRI AUC
0.975, sensitivity 98%, specificity 97%, PPV
98%, NPV 97%
Junker et al [87] 2019 Retrospective 236 bpMRI then mpMRI
in the same session
1 blinded
(experienced)
Mixed PCa defined as Gleason
score 4+3
* bpMRI did not show significant
differences in diagnostic accuracy or tumor
detection rates
* 94% of PCa were scored identically
* Omitting DCE changed PI-RADS scores in
9.75% of patients, increasing the number of
PI-RADS 3 scores by 8.89% when compared
with mpMRI
Sherrer et al [88] 2019 Retrospective 344 bpMRI then mpMRI
in the same session
1 blinded (NR) TRUS-Bx plus
MRI-TBx
Any PCa * The majority of the lesions (552/648, 85%)
were visible at bpMRI
* 15% of bpMRI-negative lesions were
positive at DCE; of these 21% (3/14) harbored
PCa
De Visschere et al [89] 2017 Retrospective 245 mpMRI scored
according to PI-
RADS v2 and with
PI-RADS v2Alt
(only T2-WI and
DWI)
NR Mixed csPCa defined as Gleason
score 3+4
* DCE was not needed for the determination
of the overall assessment category in 80.8%
(198/245) of patients
* AUC was 0.79 for both reporting methods
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Table 4 (Continued )
Author Year Study design No. of
patients
MRI reporting No. of readers
(experience)
Reference
standard
Outcome Key findings
Choi et al [90] 2019 Retrospective 113 bpMRI then mpMRI
with 2 wk interval
2 aware of
presence of PCa
(7 and 13yr)
Radical
prostatectomy
csPCa defined as Gleason
score 3+4 or volume
>0.5 cc
* No significant differences in csPCa
detection between bpMRI and mpMRI
* Higher presence of csPCa in PI-RADS
3 lesions for bpMRI compared with mpMRI
Scialpi et al [91] 2017 Retrospective 41 bpMRI then mpMRI
in the same session
2 aware of
presence of PCa
(experienced)
Radical
prostatectomy
Any PCa * For both bpMRI and mpMRI, sensitivity
was similar, and was 100% in PZ and 97.6%
and 94.7% in the entire prostate and TZ,
respectively
* bpMRI detected 181 lesions out of
131 detected at final pathology, resulting in
27.6% false-positive and 3.3% false-negative
rates
* Agreement of bpMRI and mpMRI was
identical
Gatti et al [92] 2019 Retrospective 68 bpMRI then mpMRI
with 1 mo interval
3 groups of
2 readers (1000,
300, and 100 cases
read)
Mixed Any PCa * Two expert readers performed as well in
bpMRI as in mpMRI (sensitivity = 0.91–0.96,
AUC=0.86–0.93; p  0.10)
* Readers with 300 cases performed well in
mpMRI, but significantly worse in bpMRI:
sensitivity =0.58 vs 0.91 (p<0.0001) and
AUC=0.73 vs 0.86 (p = 0.01)
Di Campli et al [93] 2018 Retrospective 85 bpMRI then mpMRI
in separate
sessions
3 blinded (7, 3, and
1yr)
Mixed csPCa defined as Gleason
score 3+4
* There was no significant difference
regarding the detection of csPCa among the
three readers between bpMRI and mpMRI
* The AUC for bpMRI and mpMRI was 0.68–
0.72 (high experience), 0.72–0.70 (medium
experience), and 0.60–0.54 (low experience)
AUC= area under the curve; bpMRI = biparametric MRI; csPCa= clinically significant prostate cancer; DCE=dynamic contrast-enhanced imaging; DWI=diffusion-weighted imaging; mpMRI =multiparametric MRI;
MRI =magnetic resonance imaging; MRI-TBx=MRI targeted biopsy; NPV=negative predictive value; NR=not reported; PCa =prostate cancer; PI-RADS=Prostate Imaging Reporting and Data System; PPV=positive
predictive value; PZ=peripheral zone; TRUS-Bx = transrectal ultrasound biopsy; T2-WI = T2-weighted imaging; TZ = transition zone.
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Fig. 2 – Overall summary of risk of bias and applicability concerns across studies based on QUADAS-2 criteria.. QUADAS-2 = Quality Assessment of
Diagnostic Accuracy Studies-2.
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EUO-306; No. of Pages 233.1. Risk of bias within studies
The overall risk of bias and applicability concern is given in
Fig. 2. The overall methodological quality of the studies was
moderate, with 17 studies having a low risk of bias and
applicability concern across all domains assessed. Supple-
mentary Fig. 1 shows the risk of bias and applicability
concerns for each study.
3.2. Magnetic field
Multiparametric MRI at 3.0 T has an increased signal-to-
noise ratio compared with 1.5 T scanners, resulting in higher
spatial resolution of T2-weighted (T2-WI) and diffusion-
weighted (DWI) imaging.
In total, seven studies assessed the value of the magnetic
field relating to mpMRI staging accuracy (Supplementary
Table 1) [14–20]. Two studies from 2004 [15,18] were
among the first reporting a comparison of 1.5 and 3.0 T
scanners even though with slightly different results. Bloch
et al [15] reported higher image quality at 3.0 T than at 1.5 T
(both with an ERC), while Sosna et al [18] reported a
comparable quality for nonendorectal 3.0 T and endorectal
1.5 T mpMRI in 40 men receiving mpMRI and subsequent
biopsy. However, these studies are not comparable given
that the ERC was not used at 3.0 T [18]. Most importantly,
only two studies addressed DWI [19,20] and thus only these
studies could evaluate the detection difference between
insignificant PCa and csPCa, as for this DWI is the most
important sequence in the peripheral zone (PZ). These
studies showed a similar Prostate Imaging Reporting and
Data System (PI-RADS) assessment for 1.5 and 3 T.
Overall, the majority of the studies did not investigate
the detection of csPCa but instead focused on the
recognition of any PCa. In this respect, both magnetic field
strengths performed equally [14,17,19], but the small sample
size and high heterogeneity of these studies make an
objective comparison difficult to conduct. In summary, no
reliable information could be obtained regarding the
detection of csPCa according to field strength regardless
of the usage of reception coils.Please cite this article in press as: Stabile A, et al. Factors Influencin
Resonance Imaging in Detecting Clinically Significant Prostate Ca
https://doi.org/10.1016/j.euo.2020.02.0053.3. Reception coil
A total of 11 studies comparing the use of mpMRI with an
external pelvic phased-array coil with or without an ERC
were included (Supplementary Table 2) [21–31]. Four
studies did not use DWI.
The use of an ERC significantly improves the signal-to-
noise ratio irrespective of the magnetic field strength,
providing T2-WI with higher spatial resolution and
potentially more accurate delineation of the
structures `in the transition zone (TZ), which is the key
factor in the assessment of csPCa in this zone. However,
the addition of an ERC is associated with increased costs,
increased artifacts [32], organ deformation, and discom-
fort for patients. Mirak et al [28] investigated the
performance of 3.0 T mpMRI with and without an ERC
to detect PCa using PI-RADS v2 guidelines, with whole-
mount histopathology as the reference standard. Two
subcohorts, with (n = 260) and without (n = 169) an ERC,
were analyzed. They concluded that detection rates for
any PCa, for the index lesion, and for csPCa were similar
in both cohorts, but there was a significantly lower
detection rate of anterior and TZ csPCa in the ERC
subcohort due to a signal drop in the anterior gland when
the ERC was used without an accompanying abdominal
phased array coil.
Another study with a direct comparison of ERC versus
non-ERC at 3.0 T [22] showed no differences in detecting
PCa using PI-RADS v2 guidelines.
Costa et al [26] reported that using an ERC at 3.0 T
provides superior sensitivity (78%) for PCa detection when
compared with standard and augmented protocols (ie,
those with twice as many signal averages; 43% and 60%,
respectively) without an ERC.
Turkbey et al [23] compared the utility of T2-WI and DWI
at 3.0 T with and without an ERC in detecting PCa in 20 men
receiving mpMRI before radical prostatectomy. The authors
demonstrated higher sensitivity when using an ERC. The
sensitivity and positive predictive value (PPV) of an ERC
versus non-ERC MRI were 76% versus 45% and 80% versus
64%, respectively.g Variability in the Performance of Multiparametric Magnetic
ncer: A Systematic Literature Review. Eur Urol Oncol (2020),
E U R O P E A N U R O L O G Y O N C O L O G Y X X X ( 2 0 1 9 ) X X X – X X X14
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1.5 T with an ERC is superior to that at 3.0 T without an ERC
in evaluating tumor conspicuity, capsular infiltration, and
seminal vesicle involvement. No significant differences
between the two techniques for the involvement of apex
and neurovascular bundles and comparable performance
for the diagnosis of capsular involvement were observed.
The authors concluded that during preoperative PCa
staging, 3.0 T mpMRI can provide diagnostic information
comparable with that of 1.5 T mpMRI with an ERC.
In summary, the use of an ERC improves signal reception,
which slightly improved sensitivity to visualize any PCa.
Only one study addressed the value of the ERC with respect
to the PI-RADS assessment of csPCa [28]. This study showed
a minor disadvantage of the ERC in detecting anterior TZ
PCa. Owing to the lack of significant evidence that the ERC
improves csPCa assessment, associated increased costs,
duration of examination, and patient discomfort, the PI-
RADS v2.1 guidelines [33] recommend the ERC to be used
only for older 1.5 T scanners with lower gradient strength
[30]. Still, the lack of standardized protocols in the available
studies makes robust comparisons hard to assess.
3.4. Assessment system
The development of a simple, structured, standardized
assessment system was one of the most considerable
challenges in prostate mpMRI. Assessment systems have
been refined during the years in order to increase the inter-
reader agreement, decrease the gap between differently
skilled radiologists, and improve communication between
radiologists and urologists. Ten studies comparing the use
of different assessment systems were included (Table 1)
[34–44]. The majority compared PI-RADS v1 [45] and v2
[33]. Differently from PI-RADS v1, PI-RADS v2 defined
dominant sequences (T2-WI for the TZ and DWI for the PZ)
and decreased the role of dynamic contrast-enhanced (DCE)
MRI [46].
Most studies reported a similar diagnostic accuracy for
both PI-RADS v1 and PI-RADS v2. However, three studies
[36,37,39] showed higher sensitivity of PI-RADS v2 for TZ
lesions, and another study by Krishna et al [40] showed that
PI-RADS v1 detected approximately 10% more tumors than
PI-RADS v2.
De Visschere et al [35] compared the performance of PI-
RADS v2 and v1 in 245 biopsy-naïve men with an elevated
level of prostate-specific antigen (PSA). They found that PI-
RADS v1 and v2 yielded similar accuracy for the detection of
csPCa. However, PI-RADS v2 had lower sensitivity than PI-
RADS v1 when a score of 3 was used as a threshold for
positive mpMRI. The authors suggested that the majority of
discrepancies were caused by a suspicious lesion in the PZ
on T2-WI but with normal DWI, scored positive with PI-
RADS v1 but negative with PI-RADS v2. Indeed, sensitivity of
PI-RADS v2 might be less when suspicious lesions on T2-WI
but negative on DWI are present in the PZ. Nonetheless, the
authors concluded that PI-RADS v2 is preferable because of
the more structured and standardized, and simpler
approach. Similar results were found by Krishna et al [40]Please cite this article in press as: Stabile A, et al. Factors Influencin
Resonance Imaging in Detecting Clinically Significant Prostate Ca
https://doi.org/10.1016/j.euo.2020.02.005who compared the two assessment systems for the
detection of csPCa lesions in 47 men before radical
prostatectomy. They found no difference in the overall
detection of csPCa but observed higher sensitivity of PI-
RADS v1 on T2-WI and DCE.
Feng et al [37] compared PI-RADS v1 and v2 in
401 consecutive biopsy-naïve men with a clinical suspicion
of PCa at 3.0 T mpMRI. Both assessment systems had a good
diagnostic performance for the detection of csPCa, but the
diagnostic accuracy increased from 0.82 to 0.88 with the use
of PI-RADS v2 compared with PI-RADS v1 when non–
biopsy-naïve men were also included. Interestingly, PI-
RADS v2 had a better performance in the TZ (0.92 vs 0.81).
Hoffmann et al [38] evaluated in 58 men whether PI-
RADS v2 was more accurate in assessing anterior prostate
csPCa than PI-RADS v1. PI-RADS v2 did not improve the
accuracy for diagnosing anterior csPCa when compared
with PI-RADS v1; however, PI-RADS v2 was more repro-
ducible between radiologists.
Schaudinn et al [43] reported moderate interobserver
reliability (k = 0.48) for PCa detection of two radiologists in
40 men before radical prostatectomy, and similar results
have been reported by Tewes et al [44], with moderate
interobserver agreement (k = 0.56) for PI-RADS v2 and fair
agreement (k = 0.39) for PI-RADS v1. The authors concluded
that PI-RADS v2 had equivalent diagnostic accuracy to PI-
RADS v1 for PCa detection, but with shorter interpretation
time for PI-RADS v2.
Two studies compared PI-RADS v1 and two different
Likert assessment systems [41,42]. Both showed good inter-
reader agreement, although one study reported higher
accuracy of the Likert scale for TZ lesions than PI-RADS v1
[42].
In summary, it is recommended to use the most recent
PI-RADS guidelines as the main assessment system given
the simplified, objective, and standardized approach as well
as its particular added value for less experienced radiolo-
gists.
3.5. Radiologist and urologist experience
The use of mpMRI to detect csPCa represents a multidisci-
plinary approach that includes skills both in acquisition and
interpretation of mpMRI and in performing MRI-TBx.
Five studies assessed the impact of reader experience on
mpMRI diagnostic performance (Table 2). Akin et al [47] and
Garcia-Reyes et al [48] were the first to test the learning
curve in prostate mpMRI reporting using whole-mount
pathology as a reference standard. They showed that a
dedicated training curriculum is useful to improve mpMRI
interpretation. Rosenkrantz et al [49] assessed the variation
of mpMRI diagnostic accuracy in detecting and localizing
csPCa among six 2nd-year radiology residents reporting
124 prostate mpMRI scans (both negative and positive).
Three out of six readers (50%) received feedback after each
examination showing the solution of the preceding case. For
readers both with and without feedback, there was an initial
rapid improvement, which slowed down after 40 examina-
tions. In the group receiving feedback, accuracy, sensitivity,g Variability in the Performance of Multiparametric Magnetic
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72–77%, and 74–82%, respectively. Interestingly, the pres-
ence of feedback did not significantly affect the accuracy as
compared with the group without feedback, showing the
effects of self-directed learning, even though readers with
feedback felt more confident. Moreover, the feedback was
more useful for TZ lesions, suggesting a higher challenge in
detecting these tumors, in line with previous studies
[47,48]. Pickersgill et al [50] conducted a retrospective
review of 459 men receiving mpMRI according to PI-RADS
(v1 implemented with v2 during the study period) and a
subsequent MRI-TBx if necessary. They showed that the
radiologist’s experience did not improve the accuracy in
csPCa detection. The authors speculated that the use of PI-
RADS might have attenuated the impact of the reader’s
experience. However, this study had serious limitations,
such as the implementation of PI-RADS v1 to v2 during the
study period and an arbitrary definition of radiologist
experience (ie, >500 mpMRI examinations). Following the
widespread use of mpMRI and the need for dedicated
training for radiologists, an online interactive case-based
website for prostate mpMRI interpretation using PI-RADS
v2 has been proposed [51]. This training course increased
the sensitivity (from 58% to 73%, p = 0.003) and the NPV
(from 69% to 78%, p = 0.049) of three 2nd-year radiology
residents who evaluated separate sets of 60 MR scans before
and after the course. Interestingly, there were no significant
improvements in the accuracy of the PI-RADS assessment
scores (from 46% to 53%, p = 0.149) [51].
The quality of MRI-TBx performance plays an equally
important role in defining the final diagnostic accuracy of
this technique. Similar to systematic ultrasound-guided
biopsy [52,53], the experience of the biopsy operator
influences significantly the outcome of an MRI-TBx, which
can be visual/cognitive, MR-ultrasound fusion, or direct
MRI-TBx [54], using either a transrectal or a transperineal
approach.
A total of eight studies assessing the learning curve of
MRI-TBx were included (Table 2). Gaziev et al [55]
demonstrated a significant gradual increase in csPCa
detection (from 27% to 63%) in 70 men receiving fusion
MRI-TBx. Similarly, Calio et al [56] reported data from three
consecutive cohorts of biopsy-naïve men receiving MRI-TBx
over a study period of 9 yr. There was a 13% increase in csPCa
detection by MRI-TBx from the early to the most recent
cohort. Meng et al [57] reported a 26% increase in csPCa
detection in 1500 men receiving repeat biopsy. Mager et al
[58] attempted in demonstrating the presence of the
learning curve effect proposing the MRI-TBx quotient,
defined as the ratio between the number of positive
targeted cores and the total number of targeted cores.
The authors showed a significant learning process, in both
detection-quotient and biopsy times; for a novice perform-
er, sufficient learning occurred after 42 procedures, reach-
ing a flattening after 63 biopsies. Kasabwala et al [59]
calculated the distance between the planned and the actual
core route in the prostatic tissue during a fusion MRI-TBx,
and demonstrated a significant improvement in MRI-TBx
accuracy after 98 cases. Halstuch et al [60] attempted toPlease cite this article in press as: Stabile A, et al. Factors Influencin
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PCa detection using a mathematical algorithm. The authors
demonstrated that at least 104 transrectal fusion MRI-TBx
and 119 transperineal fusion MRI-TBx are necessary for men
with visible PI-RADS 3 lesions, before reaching the plateau
phase of csPCa detection. In this context, Stabile et al [61]
demonstrated the presence of a learning curve affecting
csPCa detection rate even when accounting for several
confounders (such as PSA, prostate volume, and PI-RADS
score) for both visual and fusion MRI-TBx. The authors
showed a steep increase in csPCa detection during the first
60 procedures and a flattening after 80 procedures.
Interestingly, it was suggested that the transperineal
approach might be less affected by the learning curve
effect; hence, it might be easier compared with the
transrectal approach when considering MRI-TBx [61]. Final-
ly, Westhoff et al [62] proposed at least eight procedures as
experience threshold. However, this result should be
interpreted cautiously, considering the limited number of
MRI-TBx performed by each of the 22 urologists included in
this study.
In summary, when assessing the performance of mpMRI
in detecting csPCa, it is nowadays mandatory to indicate the
experience of the interpreting radiologists and biopsy-
performing urologists to support the reliability of the
findings. Less experienced readers and biopsy operators
must always be supervised by experienced readers and
operators. Moreover, mpMRI performance should be
validated internally before widespread adoption. According
to Rosenkrantz et al [49], radiologists should have reported
at least 100 expert-supervised prostate mpMRI examina-
tions after a dedicated training course, and urologists
should have performed between 60 and 100 MRI-TBx before
they potentially reach an acceptable level of csPCa
detection. Most importantly, additional quality assurance
tests are needed. Indeed, mpMRI should be performed only
in large-volume centers with validated reading assessment
[11]. Further development of quality criteria, quality
assessment, and training platforms/courses is needed.
3.6. Inter-reader variability
Although reader experience plays a substantial role in
determining mpMRI accuracy, the reporting process is
affected by almost inevitable variability among different
radiologists, which varies across different studies and
centers. Fifteen studies were included for this topic (Table 3).
Quentin et al [63] assessed the inter-reader agreement of
mpMRI using a five-point (Likert) scale [64]. The authors
showed high inter-reader reliability (PPV: 88–96%; k = 0.90)
between three blinded radiologists scoring 108 lesions.
After the introduction of PI-RADS v1 guidelines, Schim-
möller et al [65] reported the agreement of three experi-
enced radiologists scoring 164 premarked lesions. The
overall agreement was good to moderate and higher for
malignant than for benign lesions. Nonetheless, the clinical
application of PI-RADS was still premature, and a diagnostic
cutoff had not yet been proposed. Rosenkrantz et al [66]
published a series of 55 patients undergoing prostateg Variability in the Performance of Multiparametric Magnetic
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reviewed by three radiologists (two moderately experi-
enced and one inexperienced) using both PI-RADS v1 and
Likert scores. For both assessment methods, the agreement
was strong between the two experienced readers but poor
when compared with the inexperienced reader. Interest-
ingly, the Likert assessment scale had better inter-reader
reproducibility than PI-RADS score in the TZ. This was
probably due to the greater experience of the readers with
their “own” Likert assessment. Since the widespread use of
PI-RADS assessment score and the introduction of PI-RADS
v2, few studies have assessed its reproducibility, with
conflicting results. Mussi et al [67] reported moderate to
good agreement between eight radiologists with different
levels of experience in using PI-RADS v2. However, this
study is hardly applicable to clinical practice since each
reader evaluated only one MR slice containing a single
specified lesion. Similarly, Glazer et al [68] conducted a
retrospective study with three radiologists (with different
levels of experience, ranging from 1 to 11 yr) who scored
preselected lesions, with moderate agreement for PZ
(k = 0.46) and fair agreement for TZ (k = 0.36). Moreover,
the authors disclosed that PI-RADS v2 had been introduced
recently in their clinical practice, potentially influencing the
level of reproducibility. Girometti et al [69] supported the
higher level of agreement among experienced radiologists
in a monocentric study including three radiologists
analyzing 48 MRI scans, with moderate agreement for PI-
RADS cutoffs of both 3 (k = 0.57) and 4 (k = 0.63).
Nonetheless, the readers were aware of the preoperative
reason of mpMRI and hence of the presence of csPCa. Müller
et al [70] reported a poor level of agreement in a cohort of
126 men receiving two consecutive MRI scans at two
different institutions. Nonetheless, the design of this study
was not devoid of many limitations and a significant bias. In
fact, among 292 patients referred to the first institution,
126 men had mpMRI lesions considered challenging to be
reliably accessed by systematic or cognitive biopsy. Since
equipment for MRI-TBx with fusion technique was not
available in the first institution, these men were referred to
a second institution where they received a second mpMRI
scan before undergoing an MRI-targeted fusion biopsy. In
addition, all readers and authors had limited experience and
training in reading prostate MRI according to PI-RADS.
Moreover, no information regarding the used PI-RADS
version was provided. For these reasons, these results
should be considered very cautiously. Rosenkrantz et al [71]
carried out a multicenter study with six experienced
radiologists reporting at two different time points
(40 and 80 MRI scans per session) and receiving a training
session in between. The authors reported moderate
reproducibility of PI-RADS v2, suggesting no benefit from
the training session [71]. However, this study was limited by
suboptimal image quality in a number of the included
centers. Smith et al [72] provided results regarding intra-
and inter-reader agreement with a multicenter study on
four differently experienced readers. Overall, intrareader
agreement was moderate to substantial (60–77% of
agreement across different radiologists). Inter-reader agree-Please cite this article in press as: Stabile A, et al. Factors Influencin
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enced radiologists. Hansen et al [73] reported the value of a
second opinion by a subspecialized tertiary care center in
reviewing mpMRI from seven different regional hospitals.
Overall disagreement was 54% (86/158 MRI scans). Specifi-
cally, the second reading had significantly improved NPV
(0.89 vs 0.72) and PPV (0.61 vs 0.28). Greer et al [74]
reported excellent agreement on index lesion identification
(k = 0.87) and moderate agreement on individual PI-RADS
v2 category assignment (k = 0.419). Other two well-
designed studies [75,76] reported similar results, with an
area under the curve (AUC) for PCa ranging between
0.88 and 0.95 among six blinded readers [75]. Conversely,
two recent studies showed high variability in PI-RADS v2
reporting [77,78]. In particular, Sonn et al [78], in a
retrospective study of real-life mpMRI reporting by taking
into account nine radiologists and 409 patients, while
reporting a low variation in the number of lesions identified,
demonstrated high variability in PI-RADS distribution and
csPCa detection. The AUC for csPCa ranged between
0.61 and 0.81 [78]. Finally, van der Leest et al [79], in their
prospective multicenter head-to-head comparison study,
showed high inter-reader agreement of the participating
expert radiologists. This was obtained after similar training
to that described in the study of Rosenkrantz et al [49].
In summary, most of the well-designed dedicated studies
reported moderate agreement when PI-RADS v2 is taken
into consideration. Furthermore, the radiologist’s experi-
ence is crucial to increase mpMRI reproducibility, with the
major concerns related to the variability in csPCa yield and
high false-positive rates. Heterogeneity across the studies is
still high. Most of the studies on this topic did not provide
results about MRI acquisition, reader experience, or
training. There is thus still a need for standardized
mpMRI-assessment training protocols that should be
available widely, in order to improve the general perfor-
mance of mpMRI and provide more reliable data in this
context. Only Rosenkrantz et al [49] and van der Leest et al
[79] describe that radiologists should have reported at least
100 expert-supervised prostate mpMRI examinations after
a dedicated training course. Further standardization of
assessment systems, education, and certification will likely
help in reducing the subjectivity and improving the
reproducibility among less experienced readers as well.
3.7. Biparametric MRI versus mpMRI
Since the introduction of a standardized reporting system
for mpMRI [45], the role of DCE MRI has been controversial.
Indeed, PI-RADS v2 downgraded the role of DCE MRI to an
additional sequence only for upgrading a PI-RADS 3 to 4 PZ
lesion on DWI [33]. In the light of the increasing use of
mpMRI in the assessment of csPCa and the need for more
optimized and efficient protocols, the use of bpMRI based
only on T2-WI and DWI has been proposed by multiple
authors [80,81]. The benefits of omitting DCE MRI are
related to reduced examination times, reduced costs, and
avoiding the risk of adverse events related to the use of
contrast agent. Results coming from prospective trialsg Variability in the Performance of Multiparametric Magnetic
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[80,81] regarding biopsy avoidance and for reducing the
detection of insignificant cancers. Comparative studies of
mpMRI and bpMRI are mostly retrospective, with signifi-
cant differences in the methods and not negligible risk of
bias (Table 4). To the best of our knowledge, Stanzione et al
[82] showed the diagnostic accuracy of bpMRI compared
with mpMRI. The authors reported a series of 82 men
undergoing mpMRI for the suspicion of csPCa and then
receiving systematic biopsy plus eventual MRI-TBx, with
35% of patients receiving radical prostatectomy. Two
experienced radiologists blindly reported bpMRI first,
followed by mpMRI (ie, with DCE), after an interval of
20–30 d to avoid any recall bias. The overall AUC values of
bpMRI and mpMRI for csPCa detection were 0.91 and 0.93,
respectively (p > 0.05). Thestrup et al [83] reported similar
accuracies of bpMRI and mpMRI in detecting csPCa,
although without providing any formal statistical compar-
isons. Lee et al [84] compared two cohorts undergoing
mpMRI and bpMRI for a suspicion of PCa and then receiving
visual MRI-TBx in addition to standard systematic biopsy.
The authors reported a similar detection of csPCa among
men who had suspicious lesions in the bpMRI and mpMRI
groups (63% and 62%, respectively). Nonetheless, these
results should be interpreted carefully since the two cohorts
were not matched randomly.
Further studies reported promising results, although
being affected by significant bias mainly concerning the MRI
interpretation process (mpMRI and bpMRI read by the same
radiologist during the same session) [85] and the reference
standard (no biopsy result in men with negative MRI)
[86]. The similar diagnostic performance of these two
techniques was confirmed in other series [87–89] that
attempted to better identify the eventual differences.
Specifically, omitting DCE MRI was related to an increasing
rate of PI-RADS 3 lesions, slightly better specificity, and
worse sensitivity (although never significant) [87,89]. Fur-
thermore, DCE MRI was not needed for the determination of
the overall assessment category in 81% of patients [89].
Choi et al [90] compared the ability of bpMRI with that of
mpMRI in detecting the index lesion using radical
prostatectomy as the reference standard. Two independent
radiologists (7 and 13 yr of experience) retrospectively
reviewed prebiopsy MRI of 113 men using PI-RADS v2. No
significant differences were found in csPCa diagnostic
accuracy for bpMRI versus mpMRI for both readers using
PI-RADS 3 as cutoff. Interestingly, both readers reported
significantly higher sensitivity for bpMRI than for mpMRI
[90]. Furthermore, inter-reader agreement on PI-RADS
assessment score was moderate for both bpMRI (k = 0.540)
and mpMRI (k = 0.478). However, both readers of this study
were aware that all men underwent radical prostatectomy
for csPCa, and this might have affected the overall results. In
a similar study, Scialpi et al [91] evaluated the ability of
bpMRI and mpMRI to detect single lesions in a cohort of
41 men receiving radical prostatectomy. For both bpMRI and
mpMRI, the sensitivity was similar, which was 100% in PZ,
and 98% and 95% in the entire prostate and TZ, respectively.
Biparametric MRI detected 181/131 lesions at final pathol-Please cite this article in press as: Stabile A, et al. Factors Influencin
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rates [91]. Nonetheless, no information regarding readers’
background was provided and specific information regard-
ing the experience is often scarce.
In this context, Gatti et al [92] compared bpMRI and
mpMRI according to readers’ experience. The authors
conducted a retrospective study on six blinded radiologists,
divided into three groups according to the level of
experience, reviewing bpMRI and mpMRI protocols of
68 men receiving a prostate biopsy and eventual radical
prostatectomy. The authors used a modified version of PI-
RADS v2 [89] for bpMRI reading and a cutoff of 4 for both
protocols. Interestingly, the specificity was quite stable
regardless of the protocol and readers’ experience. Signifi-
cant differences were found for sensitivity and AUC in
detecting PCa index lesions, mainly related to the rate of
true positives. The effect of experience was more evident
when considering bpMRI than mpMRI. Consequently, in the
highly experienced group, the performance of bpMRI versus
mpMRI was similar (AUC: 0.86 vs 0.93, p = 0.10; true
positive: 82% vs 86%, p = 0.13). The accuracy of bpMRI
became progressively less if compared with mpMRI with
the decrease of experience (0.68 vs 0.77 in the less
experienced group). Further, the authors attempted to
provide a rough indication on the number of necessary
cases to reach an AUC and sensitivity of 0.80: 150–200 for
mpMRI and 700–800 for bpMRI [92]. Differently, Di Campli
et al [93] showed no diagnostic differences between bpMRI
and mpMRI, and no significant influence by readers’
experience.
In summary, available evidence from comparative
studies suggests that bpMRI might be a potentially valid
alternative to mpMRI, particularly for experienced readers,
on the condition that DWI is of excellent quality. These
findings have also been confirmed in a recent meta-analysis,
demonstrating the noninferiority of bpMRI and showing
overall nonsignificant higher sensitivity and lower specific-
ity of mpMRI [94]. Moreover, a recent prospective, multi-
reader, blinded direct comparison between bpMRI and
mpMRI showed similar diagnostic performance in ruling
out the presence of high-grade PCa [79].
That being said, the high methodological heterogeneity
might have represented a great confounder, and it remains
unclear how the performance of bpMRI will translate to less
experienced centers and lower-quality images. Indeed, the
assessment system used (ie, PI-RADS, dedicated bpMRI PI-
RADS), choice of the cutoff, magnetic field, choice of the
outcome (ie, PCa, csPCa), and reference standard are the
factors varying the most across the studies. Ultimately,
randomized prospective studies using noninferiority
designs, in men with variable prevalence with clinically
meaningful endpoints (biopsy avoidance, detection of csPCa,
and clinically insignificant PCa), will be needed to decide on
which patient groups can avoid contrast enhancement.
3.8. CAD and deep learning
The first study on PCa detection [95] was carried out by
Chan et al [96] in 2003 (Supplementary Table 3). The CADg Variability in the Performance of Multiparametric Magnetic
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imaging data (ie, mpMRI) with the aim to provide results
potentially related to clinical conditions (ie, PCa). Different
CAD systems have different strategies for imaging feature
analysis, with different diagnostic accuracies [97]. The
imaging analysis process includes multiple steps that can
change across different CAD systems [97,98].
The CAD has recently been assessed in aiding radiologists
during mpMRI interpretation and reporting. Interestingly,
the evaluation of CAD as an assisting tool began at a similar
time to the proposal of the first standardized assessment
system (ie, PI-RADS v1) [45,99]. The inclusion of CAD
systems in mpMRI interpretation process would potentially
overcome some of the issues affecting diagnostic accuracy,
such as reader experience, reproducibility, as well as
enhancing the accuracy of mpMRI itself.
Hambrock et al [99] published the first study evaluating
the effect of CAD for both less and more experienced
radiologists on the differentiation of benign from malignant
lesions at mpMRI. The authors demonstrated that, as the
addition of CAD significantly improved the performance of
less experienced radiologists in detecting PCa, when less
experienced radiologists used CAD, they achieved similar
performance to that of experienced radiologists. Further-
more, stand-alone CAD had similar diagnostic accuracy to
experienced readers. However, this study did not replicate a
real-life mpMRI diagnostic pathway, since the CAD system
used was able to differentiate only preidentified regions
between benign and malignant, but not PCa detection in a
whole gland. In a similar study, Niaf et al [100] demonstrated
that CAD increased the performance of both experienced and
less experienced readers (AUC increase of 2% and 4%,
respectively; p = 0.08) [100]. Litjens et al [101], in a standard
clinical scenario, showed that the combination of CAD and PI-
RADS assessment categorization achieved higher diagnostic
accuracy than PI-RADS categorization alone to discriminate
between both benign lesions versus PCa (0.88 vs 0.81, p =
0.013) and PCa versus csPCa (0.88 vs 0.78, p < 0.01) [101]. In a
similar study based on prostatectomy specimens, Wang et al
[102] demonstrated that the combination of CAD information
with PI-RADS v2 increased the clinical net benefit for PCa
identification as compared with PI-RADS categorization
alone. Further studies demonstrated the clinical utility of
quantitative analyses of ADC in improving the diagnostic
performance when compared with the scoring system alone
[103–105]. Giannini et al [106] were the first to replicate a
real-life diagnostic pathway including the use of CAD. On a
per-patient analysis, the use of CAD achieved higher
sensitivity for csPCa (91% vs 81%, p = 0.046), while specificity
was not affected. The per-lesion analysis showed a higher
number of single lesions detected with CAD assistance.
Interestingly, the average reading time with CAD was
significantly lower (60s vs 220 s; p < 0.001) [106]. Greer
et al [107] tested the effect of CAD in a multi-institutional
group of differently experienced and blinded readers
interpreting mpMRI in a cohort of men receiving radical
prostatectomy for PCa. Sensitivity increased for all experi-
ence levels; however, specificity was dependent on reader
experience. Improved sensitivity came from lesions scored asPlease cite this article in press as: Stabile A, et al. Factors Influencin
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was equal. The authors observed that CAD likely helped
readers to overcome the “satisfaction of search” limitation,
which stems from reduced detection of subsequent lesions
after one lesion. However, the improved sensitivity of CAD
was balanced by decreased specificity. It is noteworthy that
the use of CAD improved agreement between all readers
[107]. In an effort to assess the clinical value of a CAD system
in a “real-world” scenario, Gaur et al [108] tested a multi-
institutional population of 216 men receiving mpMRI. The
cases used in this study were diverse in terms of institution-
specific acquisition, MR manufacturer, and patient popula-
tion, and nine readers of different experience levels were
included. Overall, sensitivity for index lesions of mpMRI
without and with CAD assistance was comparable. The
highest benefit of CAD, as compared with mpMRI alone, was
observed for moderately experienced readers detecting TZ
csPCa. The authors concluded that CAD might help in
reducing the rate of false positivity and increasing the
sensitivity of moderately experienced readers [108]. Further-
more, recent studies confirmed the clinical utility of CAD use
in combination with a Likert score and its generalizability to
different field strengths [109,110].
Taken together, these findings suggest that CAD repre-
sents a promising tool that generally improves mpMRI
efficiency in terms of both diagnostic accuracy and reporting
time. The greatest benefit related to the use of CAD
potentially lies in improving mpMRI sensitivity for multifocal
csPCa, improving diagnostic accuracy in less experienced
readers, improving inter-reader agreement, and reducing
reporting time. Nonetheless, the majority of the available
CAD systems are limited to site-specific predefined
sequences, with most of them not considering DCE sequences
and therefore site-specific CAD algorithm raising similar
caveats to those raised when comparing bpMRI and mpMRI.
To date, CAD is limited to research use only, as several aspects
still need to be investigated and standardized.
3.9. Discussion
When assessing the role of mpMRI for PCa diagnosis, there
are multiple additional aspects that need to be taken into
account before drawing conclusions regarding clinical utility.
In this study, the factors that might influence the diagnostic
accuracy of MRI have been explored systematically. On the
basis of our findings, some points need to be discussed.
First, it is clear that all the factors described in this study
affect mpMRI accuracy, and are extremely related to each
other in determining the ability of mpMRI in detecting
csPCa. This is of crucial importance when comparing
different studies. For instance, the use of an ERC helps
increase mpMRI accuracy for anatomic image detail in the
posterior part of the prostate, but without DWI, this does
not help in better detecting csPCa. The benefit of the ERC is
related to the magnetic field strength, which varies across
the studies. In fact, according to our findings, a 3.0 T scan
without an ERC and a 1.5 T mpMRI scan with an ERC reach
similar staging accuracies, and thus anatomic detail.
However, the ERC causes compression of the PZ, whichg Variability in the Performance of Multiparametric Magnetic
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significant cancers [25]. Considering that the addition of an
ERC is also associated with increased costs, duration of
examination, and artifacts, and is uncomfortable for
patients, the use of an ERC is suggested only for older
1.5 T MR scanners. The recommended magnetic field
strength for prostate mpMRI is 3.0 T [33]. However, an
important issue that is discussed in literature is the gradient
strengths of scanners: steep gradients are crucial for good
DWI. Therefore, the steepness of gradient strength may be
more important than the field strength.
Second, the experience of radiologists and urologists is
pivotal and affects most of the factors related to mpMRI
accuracy, such as inter-reader agreement and accuracy of
different assessment systems. In this regard, different
assessment systems seem to perform differently according
to the experience of the reader. Indeed, standardization of
the use of one assessment system (ie, PI-RADS v2) might
actually help radiologists with lower experience in prostate
mpMRI to reach an acceptable accuracy level easily. In
addition, training and certification are important issues. For
example, following an expert hands-on course followed by
100 supervised (double) reads may contribute to better
interpretation quality and lower inter-reader variability
[49,79]. Similarly, the use of bpMRI appears to be most
effective for experienced readers, when good image quality
is available, whereas those with low experience might still
need DCE MRI as a backup in order to achieve acceptable
accuracy. The noninferiority of bpMRI would represent a
great step toward the widespread use of MRI, allowing a
reduction in the costs (up to $300 spared per test [84,87])
and an increase in the availability of the test (15 min saved
per patient [79,87]). With this aim in mind, well-designed
prospective trials are necessary to provide reliable evidence
and draw solid conclusions on bpMRI for PCa diagnosis
[79]. Even when assessing the use of CAD, the highest
benefit in terms of diagnostic accuracy is observed in less
experienced radiologists.
To the best of our knowledge, this is the first systematic
review exploring the different factors influencing mpMRI
accuracy in detecting csPCa. However, this study is limited by
the unsatisfactory evidence of most of the studies included,
especially related to different MRI protocols, different
outcomes, different mpMRI indications, different csPCa
prevalence, variable readers’ experience, and pathological
reference standards, with only 22% of studies having both low
risk of bias and applicability concerns. Moreover, the lack of
reliable pathological reference standards prevented the
exploration of the variability of mpMRI performance in the
presence of a negative report in the majority of studies. This
heterogeneity prevents the possibility to conduct a proper
meta-analysis on the effect of these factors. Lastly, further
factors might be included as potential influencers of mpMRI
accuracy (eg, apparent coefficient diffusion and b value,
gradient strength of the MRI scanner, type of scanner,
communication methods between radiologists and urolo-
gists, and type of study population). Nonetheless, studies
specifically addressing these further factors eligible for
inclusion in this review are scarce. These limitations arePlease cite this article in press as: Stabile A, et al. Factors Influencin
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interpreted with caution and within the appropriate context.
4. Conclusions
Even though the role of mpMRI in predicting PCa has been
demonstrated widely, several factors influence its diagnos-
tic accuracy and are affecting each other, with the
experience levels of the radiologists/biopsy operators being
the key confounders. The high heterogeneity across the
studies underlines the need for further studies that clarify
how they impact the clinical utility of mpMRI for PCa
diagnosis. Indeed, the factors assessed in this study concur
with the high variability of mpMRI performance and the
related clinical utility, consequently limiting the wide-
spread use of mpMRI. In order to deliver the benefits of
mpMRI in the diagnosis of csPCa, it is necessary to develop
expertise for both radiologists and urologists, implement
quality control, and adhere to the most recent PI-RADS
assessment guidelines. Without the standardization of
mpMRI execution and interpretation, and MRI-TBx tech-
nique, the mpMRI pathway may lead to suboptimal care
outside large-volume and expert centers mainly due to the
increased number of unnecessary biopsies, and false
positive and false negative rates [11].
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